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The evolutionary history of 2,658 cancers
Moritz Gerstung1,2,3,40*, Clemency Jolly4,40, Ignaty Leshchiner5,40, Stefan C. Dentro3,4,6,40, 
Santiago Gonzalez1,40, Daniel Rosebrock5, Thomas J. Mitchell3,7, Yulia Rubanova8,9,  
Pavana Anur10, Kaixian Yu11, Maxime Tarabichi3,4, Amit Deshwar8,9, Jeff Wintersinger8,9,  
Kortine Kleinheinz12,13, Ignacio Vázquez-García3,7, Kerstin Haase4, Lara Jerman1,14,  
Subhajit Sengupta15, Geoff Macintyre16, Salem Malikic17,18, Nilgun Donmez17,18,  
Dimitri G. Livitz5, Marek Cmero19,20, Jonas Demeulemeester4,21, Steven Schumacher5, Yu Fan11, 
Xiaotong Yao22,23, Juhee Lee24, Matthias Schlesner12, Paul C. Boutros8,25,26, David D. Bowtell27, 
Hongtu Zhu11, Gad Getz5,28,29,30, Marcin Imielinski22,23, Rameen Beroukhim5,31,  
S. Cenk Sahinalp18,32, Yuan Ji15,33, Martin Peifer34, Florian Markowetz16, Ville Mustonen35,  
Ke Yuan16,36, Wenyi Wang11, Quaid D. Morris8,9, PCAWG Evolution & Heterogeneity Working 
Group37, Paul T. Spellman10,41, David C. Wedge6,38,41, Peter Van Loo4,21,41* & PCAWG Consortium39
Cancer develops through a process of somatic evolution1,2. Sequencing data from a 
single biopsy represent a snapshot of this process that can reveal the timing of specific 
genomic aberrations and the changing influence of mutational processes3. Here, by 
whole-genome sequencing analysis of 2,658 cancers as part of the Pan-Cancer 
Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer 
Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA)4, we reconstruct 
the life history and evolution of mutational processes and driver mutation sequences 
of 38 types of cancer. Early oncogenesis is characterized by mutations in a constrained 
set of driver genes, and specific copy number gains, such as trisomy 7 in glioblastoma 
and isochromosome 17q in medulloblastoma. The mutational spectrum changes 
significantly throughout tumour evolution in 40% of samples. A nearly fourfold 
diversification of driver genes and increased genomic instability are features of later 
stages. Copy number alterations often occur in mitotic crises, and lead to 
simultaneous gains of chromosomal segments. Timing analyses suggest that driver 
mutations often precede diagnosis by many years, if not decades. Together, these 
results determine the evolutionary trajectories of cancer, and highlight opportunities 
for early cancer detection.
Similar to the evolution in species, the approximately 1014 cells in the 
human body are subject to the forces of mutation and selection1. This 
process of somatic evolution begins in the zygote and only comes to 
rest at death, as cells are constantly exposed to mutagenic stresses, 
introducing 1–10 mutations per cell division2. These mutagenic forces 
lead to a gradual accumulation of point mutations throughout life, 
observed in a range of healthy tissues5–11 and cancers12. Although these 
mutations are predominantly selectively neutral passenger mutations, 
some are proliferatively advantageous driver mutations13. The types 
of mutation in cancer genomes are well studied, but little is known 
about the times when these lesions arise during somatic evolution and 
where the boundary between normal evolution and cancer progression 
should be drawn.
Sequencing of bulk tumour samples enables partial reconstruction of 
the evolutionary history of individual tumours, based on the catalogue 
of somatic mutations they have accumulated3,14,15. These inferences 
include timing of chromosomal gains during early somatic evolution16, 
phylogenetic analysis of late cancer evolution using matched primary 
and metastatic tumour samples from individual patients17–20, and tem-
poral ordering of driver mutations across many samples21,22.
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The PCAWG Consortium has aggregated whole-genome sequenc-
ing data from 2,658 cancers4, generated by the ICGC and TCGA, and 
produced high-accuracy somatic variant calls, driver mutations, and 
mutational signatures4,23,24 (Methods and Supplementary Information).
Here, we leverage the PCAWG dataset to characterize the evolution-
ary history of 2,778 cancer samples from 2,658 unique donors across 
38 cancer types. We infer timing and patterns of chromosomal evolu-
tion and learn typical sequences of mutations across samples of each 
cancer type. We then define broad periods of tumour evolution and 
examine how drivers and mutational signatures vary between these 
epochs. Using clock-like mutational processes, we map mutation timing 
estimates into approximate real time. Combined, these analyses allow 
us to sketch out the typical evolutionary trajectories of cancer, and map 
them in real time relative to the point of diagnosis.
Reconstructing the life history of tumours
The genome of a cancer cell is shaped by the cumulative somatic aber-
rations that have arisen during its evolutionary past, and part of this 
history can be reconstructed from whole-genome sequencing data3 
(Fig. 1a). Initially, each point mutation occurs on a single chromosome 
in a single cell, which gives rise to a lineage of cells bearing the same 
mutation. If that chromosomal locus is subsequently duplicated, any 
point mutation on this allele preceding the gain will subsequently be 
present on the two resulting allelic copies, unlike mutations succeeding 
the gain, or mutations on the other allele. As sequencing data enable the 
measurement of the number of allelic copies, one can define categories 
of early and late clonal variants, preceding or succeeding copy number 
gains, as well as unspecified clonal variants, which are common to all 
cancer cells, but cannot be timed further. Lastly, we identify subclonal 
mutations, which are present in only a subset of cells and have occurred 
after the most recent common ancestor (MRCA) of all cancer cells in 
the tumour sample (Supplementary Information).
The ratio of duplicated to non-duplicated mutations within a gained 
region can be used to estimate the time point when the gain hap-
pened during clonal evolution, referred to here as molecular time, 
which measures the time of occurrence relative to the total num-
ber of (clonal) mutations. For example, there would be few, if any, 
co-amplified early clonal mutations if the gain had occurred right 
after fertilization, whereas a gain that happened towards the end of 
clonal tumour evolution would contain many duplicated mutations14 
(Fig. 1a, Methods).
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Fig. 1 | Timing clonal copy number gains using allele frequencies of point 
mutations. a, Principles of timing mutations and copy number gains based on 
whole-genome sequencing. The number of sequencing reads reporting point 
mutations can be used to discriminate variants as early or late clonal (green or 
purple, respectively) in cases of specific copy number gains, as well as clonal 
(blue) or subclonal (red) in cases without. b, Annotated point mutations in one 
sample based on VAF (top), copy number (CN) state and structural variants 
(middle), and resulting timing estimates (bottom). LOH, loss of heterozygosity. 
c, Overview of the molecular timing distribution of copy number gains across 
cancer types. Pie charts depict the distribution of the inferred mutation time 
for a given copy number gain in a cancer type. Green denotes early clonal gains, 
with a gradient to purple for late gains. The size of each chart is proportional to 
the recurrence of this event. Abbreviations for each cancer type are defined 
in Supplementary Table 1. d, Heat maps representing molecular timing 
estimates of gains on different chromosome arms (x axis) for individual 
samples (y axis) for selected tumour types. e, Temporal patterns of two  
near-diploid cases illustrating synchronous gains (top) and asynchronous 
gains (bottom). f, Left, distribution of synchronous and asynchronous gain 
patterns across samples, split by WGD status. Uninformative samples  
have too few or too small gains for accurate timing. Right, the enrichment  
of synchronous gains in near-diploid samples is shown by systematic 
permutation tests. g, Proportion of copy number segments (n = 90,387) with 
secondary gains. Error bars denote 95% credible intervals. ND, near diploid.  
h, Distribution of the relative latency of n = 824 secondary gains with available 
timing information, scaled to the time after the first gain and aggregated per 
chromosome.
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These analyses are illustrated in Fig. 1b. As expected, the variant 
allele frequencies (VAFs) of somatic point mutations cluster around 
the values imposed by the purity of the sample, local copy number 
configuration and identified subclonal populations. The depicted 
clear cell renal cell carcinoma has gained chromosome arm 5q at an 
early molecular time as part of an unbalanced translocation t(3p;5q), 
which confirms the notion that this lesion often occurs in adolescence 
in this cancer type16. At a later time point, the sample underwent a whole 
genome duplication (WGD) event, duplicating all alleles, including the 
derivative chromosome, in a single event, as evidenced by the mutation 
time estimates of all copy number gains clustering around a single time 
point, independently of the exact copy number state.
Timing patterns of copy number gains
To systematically examine the mutational timing of chromosomal gains 
throughout the evolution of tumours in the PCAWG dataset, we applied 
this analysis to the 2,116 samples with copy number gains suitable for 
timing (Supplementary Information). We find that chromosomal gains 
occur across a wide range of molecular times (median molecular time 
0.60, interquartile range (IQR) 0.10–0.87), with systematic differences 
between tumour types, whereas within tumour types, different chro-
mosomes typically show similar distributions (Fig. 1c, Extended Data 
Figs. 1, 2, Supplementary Information). In glioblastoma and medul-
loblastoma, a substantial fraction of gains occurs early in molecular 
time. By contrast, in lung cancers, melanomas and papillary kidney 
cancers, gains arise towards the end of the molecular timescale. Most 
tumour types, including breast, ovarian and colorectal cancers, show 
relatively broad periods of chromosomal instability, indicating a very 
variable timing of gains across samples.
There are, however, certain tumour types with consistently early 
or late gains of specific chromosomal regions. Most pronounced is 
glioblastoma, in which 90% of tumours contain single copy gains of 
chromosome 7, 19 or 20 (Fig. 1c, d). Notably, these gains are consistently 
timed within the first 10% of molecular time, which suggests that they 
arise very early in a patient’s lifetime. In the case of trisomy 7, typically 
less than 3 out of 600 single nucleotide variants (SNVs) on the whole 
chromosome precede the gain (Extended Data Fig. 3a, b). On the basis 
of a mutation rate of µ = 4.8 × 10−10 to 3.0 × 10−9 SNVs per base pair per 
division25, this indicates that the trisomy occurs within the first 6–39 
cell divisions, suggesting a possible early developmental origin, in 
agreement with somatic mosaicisms observed in the healthy brain26. 
Similarly, the duplications leading to isochromosome 17q in medul-
loblastoma are timed exceptionally early (Extended Data Fig. 3c, d).
Notably, we observed that gains in the same tumour often appear 
to occur at a similar molecular time, pointing towards punctuated 
bursts of copy number gains involving most gained segments (Fig. 1e). 
Although this is expected in tumours with WGD (Fig. 1b), it may seem 
surprising to observe synchronous gains in near-diploid tumours, par-
ticularly as only 6% of co-amplified chromosomal segments were linked 
by a direct inter-chromosomal structural variant. Still, synchronous 
gains are frequent, occurring in 57% (468 out of 815) of informative 
near-diploid tumours, 61% more frequently than expected by chance 
(P < 0.01, permutation test; Fig. 1f). Because most arm-level gains incre-
ment the allele-specific copy number by 1 (80–90%; Fig. 1g), it seems 
that these gains arise through mis-segregation of single copies during 
anaphase. This notion is further supported by the observation that in 
about 85% of segments with two gains of the same allele, the second 
gain appears with noticeable latency after the first (Fig. 1h). Therefore, 
the extensive chromosome-scale copy number aberrations observed 
in many cancer genomes are seemingly caused by a limited number 
of events—possibly by merotelic attachments of chromosomes to 
multipolar mitotic spindles27, or as a consequence of negative selection 
of individual aneuploidies28—offering an explanation for observations 
of punctuated evolution in breast and colorectal cancer29,30.
Timing of point mutations in driver genes
As outlined above, point mutations (SNVs and insertions and deletions 
(indels)) can be qualitatively assigned to different epochs, allowing 
the timing of driver mutations. Out of the 47 million point mutations 
in 2,583 unique samples, 22% were early clonal, 7% late clonal, 53% 
unspecified clonal and 17% subclonal (Fig. 2a). Among a panel of 453 
cancer driver genes, 5,913 oncogenic point mutations were identified4, 
of which 29% were early clonal, 5% late clonal, 56% unspecified clonal 
and 8% subclonal. It thus emerges that common drivers are enriched in 
the early clonal and unspecified clonal categories and depleted in the 
late clonal and subclonal ones, indicating a preferential early timing 
(Fig. 2b). For example, driver mutations in TP53 and KRAS are 12 and 8 
times enriched in early clonal stages, respectively. For TP53, this trend 
is independent of tumour type (Fig. 2c). Mutations in PIK3CA are two 
times more frequently clonal than expected, and non-coding changes 
near the TERT gene are three times more frequently early clonal.
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Fig. 2 | Timing of point mutations shows that recurrent driver gene 
mutations occur early. a, Top, distribution of point mutations over different 
mutation periods in n = 2,778 samples. Middle, timing distribution of driver 
mutations in the 50 most recurrent lesions across n = 2,583 white listed 
samples from unique donors. Bottom, distribution of driver mutations across 
cancer types; colour as defined in the inset. b, Relative timing of the 50 most 
recurrent driver lesions, calculated as the odds ratio of early versus late clonal 
driver mutations versus background, or clonal versus subclonal. Error bars 
denote 95% confidence intervals derived from bootstrap resampling. Odds 
ratios overlapping 1 in less than 5% of bootstrap samples are considered 
significant (coloured). The underlying number of samples with a given 
mutation is shown in a. c, Relative timing of TP53 mutations across cancer 
types, as in b. The number of samples is defined in the x-axis labels.  
d, Estimated number of unique lesions (genes) contributing 50% of all driver 
mutations in different timing epochs across n = 2,583 unique samples, 
containing n = 5,756 driver mutations with available timing information. Error 
bars denote the range between 0 and 1 pseudocounts; bars denote the average 
of the two values. NA, not applicable; NS, not significant.
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Aggregating the clonal status of all driver point mutations over 
time reveals an increased diversity of driver genes mutated at 
later stages of tumour development: 50% of all early clonal driver 
mutations occur in just 9 genes, whereas 50% of late and subclonal 
mutations occur in approximately 35 different genes each, a nearly 
fourfold increase (Fig. 2d). Consistent with previous studies of indi-
vidual tumour types31–34, these results suggest that, in general, the 
very early events in cancer evolution occur in a constrained set of 
common drivers, and a more diverse array of drivers is involved in 
late tumour development.
Relative timing of somatic driver events
Although timing estimates of individual events reflect evolutionary 
periods that differ from one sample to another, they define in part 
the order in which driver mutations and copy number alterations have 
occurred in each sample (Fig. 3a–d). As confirmed by simulations, 
aggregating these orderings across samples defines a probabilistic 
ranking of lesions (Fig. 3a), recapitulating whether each mutation 
occurs preferentially early or late during tumour evolution (Extended 
Data Figs. 4, 5, Supplementary Information).
In colorectal adenocarcinoma, for example, we find APC mutations 
to have the highest odds of occurring early, followed by KRAS, loss 
of 17p and TP53, and SMAD4 (Fig. 3b, e). Whole-genome duplications 
occur after tumours have accumulated several driver mutations, 
and many chromosomal gains and losses are typically late. These 
results are in agreement with the classical APC-KRAS-TP53 pro-
gression model of Fearon and Vogelstein35, but add considerable 
detail.
In many cancer types, the sequence of events during cancer progres-
sion has not previously been determined in detail. For example, in 
pancreatic neuroendocrine cancers, we find that many chromosomal 
losses, including those of chromosomes 2, 6, 11 and 16, are among 
the earliest events, followed by driver mutations in MEN1 and DAXX 
(Fig. 3c, f). WGD events occur later, after many of these tumours have 
reached a pseudo-haploid state due to widespread chromosomal 
losses. In glioblastoma, we find that the loss of chromosome 10, and 
driver mutations in TP53 and EGFR are very early, often preceding 
early gains of chromosomes 7, 19 and 20 (Fig. 3d, g). Mutations in the 
TERT promoter tend to occur at early to intermediate time points, 
whereas other driver mutations and copy number changes tend to 
be later events.
Across cancer types, we typically find TP53 mutations among the 
earliest events, as well as losses of chromosome 17 (Supplementary 
Information). WGD events usually have an intermediate ranking, and 
most copy number changes occur later. Losses typically precede gains, 
and consistent with the results above, common drivers typically occur 
before rare drivers.
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Fig. 3 | Aggregating single-sample ordering reveals typical timing of  
driver mutations. a, Schematic representation of the ordering process.  
b–d, Examples of individual patient trajectories (partial ordering relationships), 
the constituent data for the ordering model process. e–g, Preferential ordering 
diagrams for colorectal adenocarcinoma (ColoRect–AdenoCA) (e), pancreatic 
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highlighted. The prevalence of the event type in the cohort is displayed as a bar 
plot on the right.
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Timing of mutational signatures
The cancer genome is shaped by various mutational processes over 
its lifetime, stemming from exogenous and cell-intrinsic DNA dam-
age, and error-prone DNA replication, leaving behind characteristic 
mutational spectra, termed mutational signatures24,36. Stratifying 
mutations by their clonal allelic status, we find evidence for a changing 
mutational spectrum between early and late clonal time points in 29% 
(530 out of 1,852) of informative samples (P < 0.05, Bonferroni-adjusted 
likelihood-ratio test), typically changing the spectrum by 19% (median 
absolute difference; range 4–66%) (Fig. 4a, b, Extended Data Fig. 6). 
Similarly, 30% of informative samples (729 out of 2,387) displayed 
changes of their mutation spectrum between the clonal and subclonal 
state, with median difference of 21% (range 3–72%). Combined, the 
mutation spectrum changes throughout tumour evolution in 40% of 
samples (1,069 out of 2,688).
To quantify whether the observed temporal changes can be attrib-
uted to known and suspected mutational processes, we decom-
posed the mutational spectra at each time point into a catalogue of 
57 mutational signatures, including double base substitution and indel 
signatures24 (Methods).
In general, these mutational signatures display a predominantly 
undirected temporal variability over several orders of magnitude 
(Fig. 4c, d, Extended Data Fig. 7). In addition, several signatures dem-
onstrate distinct temporal trends. As one may expect, signatures of 
exogenous mutagens are predominantly active in the early clonal 
stages of tumorigenesis. These include tobacco smoking in lung adeno-
carcinoma (signature SBS4, median fold change 0.43, IQR 0.31–0.72), 
consistent with previous reports37,38, and ultraviolet light exposure in 
melanoma (SBS7; median fold change 0.16, IQR 0.09–0.43). Another 
strong decrease over time is found for a signature of unknown aetiol-
ogy, SBS12, which acts mostly in liver cancers (median fold change 0.22, 
IQR 0.06–0.41). In chronic lymphoid leukaemia, there was a 20-fold 
relative decrease in mutations associated with somatic hypermuta-
tion (SBS9; median fold change 0.05, IQR 0.02–0.43) from clonal to 
subclonal stages.
Some mutational processes tend to increase throughout cancer 
evolution. For example, we see that APOBEC mutagenesis (SBS2 and 
SBS13) increases in many cancer types from the early to late clonal 
stages (median fold change 2.0, IQR 0.8–3.6), as does a newly described 
signature SBS38 (median fold 3.6, IQR 1.8–11). Signatures of defective 
mismatch repair (SBS6, 14, 15, 20, 21, 26 and 44) increase from clonal 
to subclonal stages (median fold 1.8, IQR 1.2–3.0).
Chronological time estimates
The molecular timing data presented above do not measure the 
occurrence of events in chronological time. If the rate at which 
mutations are acquired per year in each sample was constant, the 
chronological time would simply be the product of the estimated 
molecular timing and age at diagnosis. However, this relation will be 
nonlinear if the mutation rate changes over time, and is inflated by 
acquired mutational processes, as suggested by the analysis in the 
previous section. Some of these issues can be mitigated by count-
ing only mutations contributed by endogenous and less variable 
mutational processes, such as CpG-to-TpG mutations (hereafter 
CpG>TpG) caused by spontaneous deamination of 5-methyl-cytosine 
to thymine at CpG dinucleotides, which have been proposed as 
a molecular clock12. Our supplementary analysis suggests that, 
although the baseline CpG>TpG mutation rate in cancers is very 
close to that in normal cells, there appears to be a moderate increase 
(1–10 times, adding between 20 and 40% of mutations) in cancers 
(Extended Data Fig. 8). As this shifts chronological timing estimates, 
we model different scenarios of the evolution of the CpG>TpG muta-
tion rate (Fig. 5a).
Applying this logic to time WGDs, which yield sufficient numbers of 
CpG>TpG mutations, demonstrates that they occur several years and 
possibly even a decade or more before diagnosis in some cancer types, 
under a range of scenarios of mutation rate increase (Fig. 5b, Extended 
Data Fig. 9). A notable example is ovarian adenocarcinoma, which 
appears to have a median latency of more than 10 years. This holds 
true even under a scenario of a CpG>TpG rate increase of 20-fold, which 
would be far beyond the 7.5-fold rate increase observed in matched 
primary and relapse samples39 (Extended Data Fig. 8f). Notably, these 
results suggest WGD may occur throughout the entire female repro-
ductive life (Extended Data Fig. 9b). The latency between the MRCA 
and the last detectable subclone is shorter, typically several months 
to years (Fig. 5c).
These timescales of cancer evolution are further supported by the 
fact that progression of most known precancerous lesions to carcino-
mas usually spans many years, if not decades40–45. Our data corroborate 
these timescales and extend them to cancer types without detectable 
premalignant conditions, raising the hope that these tumours could 
also be detected in less malignant stages.
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Fig. 4 | Dynamic mutational processes during early and late clonal tumour 
evolution. a, Example of tumours with substantial changes between mutation 
spectra of early (left) and late (right) clonal time points. The attribution of 
mutations to the most characteristic signatures are shown. b, Example of clonal-
to-subclonal mutation spectrum change. c, Fold changes between relative 
proportions of early and late clonal mutations attributed to individual 
mutational signatures. Points are coloured by tissue type. Data are shown for 
samples (n = 530) with measurable changes in their overall mutation spectra and 
restricted to signatures active in at least 10 samples. Box plots demarcate the first 
and third quartiles of the distribution, with the median shown in the centre and 
whiskers covering data within 1.5× the IQR from the box. d, Fold changes between 
clonal and subclonal periods in samples (n = 729) with measurable changes in 
their mutation spectra, analogous to c.
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Discussion
To our knowledge, our study presents the first large-scale genome-wide 
reconstruction of the evolutionary history of cancers, reconstructing 
both early (pre-cancer) and later stages of 38 cancer types. This is facili-
tated by the timing of copy number gains relative to all other events 
in the genome, through multiplicity and clonal status of co-amplified 
point mutations. However, several limitations exist (Supplementary 
Information). Perhaps most importantly, molecular timing is based 
on point mutations and is therefore subject to changes in mutation 
rate. Notably, healthy tissues acquire point mutations at rates not too 
dissimilar from those seen in cancers, particularly when considering 
only endogenous mutational processes, and furthermore, some tissues 
are riddled with microscopic clonal expansions of driver gene 
mutations5–9,11. This is direct evidence that the life history of almost 
every cell in the human body, including those that develop into cancer, 
is driven by somatic evolution.
Together, the data presented here enable us to draw approximate 
timelines summarizing the typical evolutionary history of each cancer 
type (Fig. 6, Supplementary Information for all other cancer types). 
These make use of the qualitative timing of point mutations and copy 
number alterations, as well as signature activities, which can be inter-
leaved with the chronological estimates of WGD and the appearance 
of the MRCA.
It is remarkable that the evolution of practically all cancers displays 
some level of order, which agrees very well with, and adds much detail 
to, established models of cancer progression35,46. For example, TP53 
with accompanying 17p deletion is one of the most frequent initiating 
mutations in a variety of cancers, including ovarian cancer, in which it 
is the hallmark of its precancerous precursor lesions47. Furthermore, 
the list of typically early drivers includes most other highly recurrent 
cancer genes, such as KRAS, TERT and CDKN2A, indicating a preferred 
role in early and possibly even pre-cancer evolution. This initially con-
strained set of genes broadens at later stages of cancer development, 
suggesting an epistatic fitness landscape canalizing the first steps of 
cancer evolution. Over time, as tumours evolve, they follow increasingly 
diverse paths driven by individually rare driver mutations, and by copy 
number alternations. However, none of these trends is absolute, and 
the evolutionary paths of individual tumours are highly variable, show-
ing that cancer evolution follows trends, but is far from deterministic.
Our study sheds light on the typical timescales of in vivo tumour 
development, with initial driver events seemingly occurring up to 
decades before diagnosis, demonstrating how cancer genomes are 
shaped by a lifelong process of somatic evolution, with fluid bound-
aries between normal ageing processes5–11 and cancer evolution. 
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Fig. 5 | Approximate chronological timing inference suggests a timescale of 
cancer evolution of several years. a, Mapping of molecular timing estimates to 
chronological time under different scenarios of increases in the CpG>TpG 
mutation rate. A greater increase before diagnosis indicates an inflation of the 
mutation timescale. b, Median latency between WGDs and the last detectable 
subclone before diagnosis under different scenarios of CpG>TpG mutation rate 
increases for n = 569 non-hypermutant cancers with at least 100 informative 
SNVs, low tumour in normal contamination and at least five samples per 
tumour histology. c, Median latency between the MRCA and the last detectable 
subclone before diagnosis for different CpG>TpG mutation rate changes in 
n = 1,921 non-hypermutant samples with low tumour in normal contamination 
and at least 5 cases per cancer type.
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Fig. 6 | Typical timelines of tumour development. a–d, Timelines 
representing the length of time, in years, between the fertilized egg and the 
median age of diagnosis for colorectal adenocarcinoma (a), squamous cell lung 
cancer (b), ovarian adenocarcinoma (c) and pancreatic adenocarcinoma (d). 
Real-time estimates for major events, such as WGD and the emergence of the 
MRCA, are used to define early, variable, late and subclonal stages of tumour 
evolution approximately in chronological time. The range of chronological 
time estimates according to varying clock mutation acceleration rates is shown 
as well, with tick marks corresponding to 1×, 2.5×, 5×, 7.5×, 10× and 20×. Driver 
mutations and copy number alterations (CNA) are shown in each stage 
according to their preferential timing, as defined by relative ordering. 
Mutational signatures (Sigs) that, on average, change over the course of tumour 
evolution, or are substantially active but not changing, are shown in the epoch in 
which their activity is greatest. DBS, double base substitution; SBS, single base 
substitutions. Where applicable, lesions with a known timing from the literature 
are annotated; dagger symbols denotes events that were found to have a 
different timing; asterisk symbol denotes events that agree with our timing.
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Nevertheless, the presence of genetic aberrations with such long 
latency raises hopes that aberrant clones could be detected early, 
before reaching their full malignant potential.
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Methods
Dataset
The PCAWG series consists of 2,778 tumour samples (2,703 white listed, 
75 grey listed) from 2,658 donors. All samples in this dataset underwent 
whole-genome sequencing (minimum average coverage 30× in the 
tumour, 25× in the matched normal samples), and were processed 
with a set of project-specific pipelines for alignment, variant calling, 
and quality control4. Copy number calls were established by combin-
ing the output of six individual callers into a consensus using a multi-
tier approach, resulting in a copy number profile, a purity and ploidy 
value and whether the tumour has undergone a WGD (Supplementary 
Information). Consensus subclonal architectures have been obtained 
by integrating the output of 11 subclonal reconstruction callers, after 
which all SNVs, indels and structural variants are assigned to a muta-
tion cluster using the MutationTimer.R approach (Supplementary 
Information). Driver calls have been defined by the PCAWG Driver 
Working Group4, and mutational signatures are defined by the PCAWG 
Signatures Working Group24. A more detailed description can be found 
in Supplementary Information, section 1.
Data accrual was based on sequencing experiments performed by 
individual member groups of the ICGC and TCGA, as described in an 
associated study4. As this is a meta-analysis of existing data, power 
calculations were not performed and the investigators were not blinded 
to cancer diagnoses.
Timing of gains
We used three related approaches to calculate the timing of copy num-
ber gains (see Supplementary Information, section 2). In brief, the 
common feature is that the expected VAF of a mutation (E) is related to 
the underlying number of alleles carrying a mutation according to the 
formula: E[X] = nmfρ/[N (1 − ρ) + Cρ], in which X is the number of reads, 
n denotes the coverage of the locus, the mutation copy number m is 
the number of alleles carrying the mutation (which is usually inferred), 
f is the frequency of the clone carrying the given mutation (f = 1 for 
clonal mutations). N is the normal copy number (2 on autosomes, 1 or 
2 for chromosome X and 0 or 1 for chromosome Y), C is the total copy 
number of the tumour, and ρ is the purity of the sample.
The number of mutations nm at each allelic copy number m then 
informs about the time when the gain has occurred. The basic formulae 
for timing each gain are, depending on the copy number configuration:
T n n nCopy number 2 + 1 : = 3 /(2 + )2 2 1
T n n nCopy number 2 + 2 : = 2 /(2 + )2 2 1
T n n nCopy number 2 + 0 : = 2 /(2 + )2 2 1
in which 2 + 1 refers to major and minor copy number of 2 and 1, respec-
tively. Methods differ slightly in how the number of mutations present 
on each allele are calculated and how uncertainty is handled (Supple-
mentary Information).
Timing of mutations
The mutation copy number m and the clonal frequency f is calculated 
according to the principles indicated above. Details can be found in Sup-
plementary Information, section 2. Mutations with f = 1 are denoted 
as ‘clonal’, and mutations with f < 1 as ‘subclonal’. Mutations with f = 1 
and m > 1 are denoted as ‘early clonal’ (co-amplified). In cases with f = 1, 
m = 1 and C > 2, mutations were annotated as ‘late clonal’, if the minor 
copy number was 0, otherwise ‘clonal’ (unspecified).
Timing of driver mutations
A catalogue of driver point mutations (SNVs and indels) was provided 
by the PCAWG Drivers and Functional Interpretation Group4. The timing 
category was calculated as above. From the four timing categories, the 
odds ratios of early/late clonal and clonal (early, late or unspecified 
clonal)/subclonal were calculated for driver mutations against the 
distribution of all other mutations present in fragments with the same 
copy number composition in the samples with each particular driver. 
The background distribution of these odds ratios was assessed with 
1,000 bootstraps (Supplementary Information, section 4.1).
Integrative timing
For each pair of driver point mutations and recurrent copy number 
alterations, an ordering was established (earlier, later or unspecified). 
The information underlying this decision was derived from the timing 
of each driver point mutation, as well as from the timing status of clonal 
and subclonal copy number segments. These tables were aggregated 
across all samples and a sports statistics model was employed to calcu-
late the overall ranking of driver mutations. A full description is given 
in Supplementary Information, section 4.2.
Timing of mutational signatures
Mutational trinucleotide substitution signatures, as defined by the 
PCAWG Mutational Signatures Working Group24, were fit to samples 
with observed signature activity, after splitting point mutations into 
either of the four epochs. A likelihood ratio test based on the multi-
nomial distribution was used to test for differences in the mutation 
spectra between time points. Time-resolved exposures were calcu-
lated using non-negative linear least squares. Full details are given in 
Supplementary Information, section 5.
Real-time estimation of WGD and MRCA
CpG>TpG mutations were counted in an NpCpG context, except for 
skin–melanoma, in which CpCpG and TpCpG were excluded owing to 
the overlapping UV mutation spectrum. For visual comparison, the 
number of mutations was scaled to the effective genome size, defined as 
the 1/mean(mi/Ci), in which mi is the estimated number of allelic copies 
of each mutation, and Ci is the total copy number at that locus, thereby 
scaling to the final copy number and the time of change.
A hierarchical Bayesian linear regression was fit to relate the age at 
diagnosis to the scaled number of mutations, ensuring positive slope 
and intercept through a shared gamma distribution across cancer types.
For tumours with several time points, the set of mutations shared 
between diagnosis and relapse (nD) and those specific to the relapse (nR) 
was calculated. The rate acceleration was calculated as: a = nR/nD × tD/tR. 
This analysis was performed separately for all substitutions and for 
CpG>TpG mutations.
On the basis of these analyses, a typical increase of 5× for most cancer 
types was chosen, with a lower value of 2.5× for brain cancers and a 
value of 7.5× for ovarian cancer.
The correction for transforming an estimate of a copy number gain 
in mutation time into chronological time depends not only on the rate 
acceleration, but also on the time at which this acceleration occurred. 
As this is generally unknown, we performed Monte Carlo simulations 
of rate accelerations spanning an interval of 15 years before diagnosis, 
corresponding roughly to 25% of time for a diagnosis at 60 years of age, 
noting that a 5× rate increase over this duration yields an offset of about 
33% of mutations, compatible with our data. Subclonal mutations were 
assumed to occur at full acceleration. The proportion of subclonal 
mutations was divided by the number of identified subclones, thus 
conservatively assuming branching evolution. Full details are given 
in Supplementary Information, section 6.
Cancer timelines
The results from each of the different timing analyses are combined in 
timelines of cancer evolution for each tumour type (Fig. 6 and Supple-
mentary Information). Each timeline begins at the fertilized egg, and 
spans up to the median age of diagnosis within each cohort. Real-time 
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estimates for WGD and the MRCA act as anchor points, allowing us 
to roughly map the four broadly defined time periods (early clonal, 
intermediate, late clonal and subclonal) to chronological time during a 
patient’s lifespan. Specific driver mutations or copy number alterations 
can be placed within each of these time frames based on their ordering 
from the league model analysis. Signatures are shown if they typically 
change over time (95% confidence intervals of mean change not over-
lapping 0), and if they are strongly active (contributing at least 10% 
mutations to one time point). Signatures are shown on the timeline in 
the epoch of their greatest activity. Where an event found in our study 
has a known timing in the literature, the agreement is annotated on 
the timeline; with an asterisk denoting an agreed timing, and dagger 
symbol denoting a timing that is different to our results. Full details 
are given in Supplementary Information, section 7.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
Somatic and germline variant calls, mutational signatures, subclonal 
reconstructions, transcript abundance, splice calls and other core 
data generated by the ICGC/TCGA PCAWG Consortium are described 
elsewhere4 and available for download at https://dcc.icgc.org/releases/
PCAWG. Further information on accessing the data, including raw read 
files, can be found at https://docs.icgc.org/pcawg/data/. In accord-
ance with the data access policies of the ICGC and TCGA projects, most 
molecular, clinical and specimen data are in an open tier that does 
not require access approval. To access information that could poten-
tially identify participants, such as germline alleles and underlying 
sequencing data, researchers will need to apply to the TCGA Data Access 
Committee (DAC) via dbGaP (https://dbgap.ncbi.nlm.nih.gov/aa/wga.
cgi?page=login) for access to the TCGA portion of the dataset, and to 
the ICGC Data Access Compliance Office (DACO; http://icgc.org/daco) 
for the ICGC portion. In addition, to access somatic SNVs derived from 
TCGA donors, researchers will also need to obtain dbGaP authorization. 
Datasets used and results presented in this study, including timing 
estimates for copy number gains, chronological estimates of WGD and 
MRCA, as well as mutation signature changes, are described in Sup-
plementary Note 3 and are available at https://dcc.icgc.org/releases/
PCAWG/evolution-heterogeneity.
Code availability
The core computational pipelines used by the PCAWG Consortium for 
alignment, quality control and variant calling are available to the public 
at https://dockstore.org/search?search=pcawg under the GNU General 
Public License v3.0, which allows for reuse and distribution. Analysis 
code presented in this study is available through the GitHub reposi-
tory https://github.com/PCAWG-11/Evolution. This archive contains 
relevant software and analysis workflows as submodules, which include 
code for timing copy number gains, point mutations and mutation 
signatures, real-time timing and evolutionary league model analysis, 
as well as scripts to generate the figures presented: CancerTiming 
(v.3.1.8), MutationTimeR (v.0.1), PhylogicNDT (v.1.1) and a series of 
custom scripts (v. 1.0), with detailed versions of other packages used.
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Extended Data Fig. 1 | Summary of all results obtained for colorectal 
adenocarcinoma (n = 60) as an example. a, Clustered heat maps of mutational 
timing estimates for gained segments, per patient. Colours as indicated in 
main text: green represents early clonal events, purple represents late clonal. 
b, Relative ordering of copy number events and driver mutations across all 
samples. c, Distribution of mutations across early clonal, late clonal and 
subclonal stages, for the most common driver genes. A maximum of 10 driver 
genes are shown. d, Clustered mutational signature fold changes between early 
clonal and late clonal stages, per patient. Green and purple indicate, 
respectively, a signature decrease and increase in late clonal from early clonal 
mutations. Inactive signatures are coloured white. e, As in d but for clonal 
versus subclonal stages. Blue indicates a signature decrease and red an 
increase in subclonal from clonal mutations. f, Typical timeline of tumour 
development. Similar result summaries for all other cancer types can be found 
in the Supplementary Information (pages 46–77).
Article
Extended Data Fig. 2 | Comparison of methods used for timing of individual copy number gains. a, b, Pairwise comparison of the three approaches for timing 
individual copy number gains. c, Comparison using simulated data, showing high concordance.
Extended Data Fig. 3 | Early copy number gains in brain cancers. a, Three 
illustrative examples of glioblastoma with trisomy 7. The red arrow depicts the 
expected VAF cluster of point mutations preceding trisomy 7, which usually 
contains less than three SNVs. b, Distributions of the number of SNVs 
preceding trisomy 7 and total number of mutations on chromosome (chr) 7 in 
n = 34 GBM samples with trisomy 7. c, Medulloblastoma example with 
isochromosome 17q. d, Distributions of SNVs on 17q in n = 95 samples with 
isochromosome 17q; 74 out of 95 samples have less than 1 SNV preceding the 
isochromosome.
Article
Extended Data Fig. 4 | See next page for caption.
Extended Data Fig. 4 | Validation of relative ordering model reconstruction 
based on simulated cohorts of whole-genome samples. a, Relative ordering 
model (PhylogicNDT LeagueModel) results for a simulated cohort of samples 
(n = 100) from a single generalized relative order of events (with varied 
prevalence) showing high concordance with the true trajectory. Probability 
distributions show the uncertainty of timing for specific events in the cohort. 
b, Relative ordering model results on a simulated cohort of samples (n = 95) 
from a complex mixture of trajectories with different order of events showing 
high concordance with the expected average trajectory. c, Estimation of 
accuracy of the relative ordering model reconstruction by simulation of a  
set of 100 cohorts (n(samples) = 100) with random trajectory mixtures and 
quantifying the distance in log odds early/late from perfect ordering. For the 
vast majority of events (even with low number of occurrences in the cohort), 
the log odds error does not exceed 1, confirming that very few events would 
switch between timing categories. The inset box corresponds to the first and 
third quartiles of the distribution, the horizontal line indicates the median and 
whiskers include data within 1.5× the IQR from the box. d, Simulated data show 
concordant timing in cohorts with WGD (n = 245). Exclusion of samples with 
WGD (right, n = 242) introduces only a mild drop in accuracy, indicating that 
WGD is beneficial but not necessary for the reconstruction. Red dot = true rank. 
e, Estimated log odds in observed data including WGD (left, n = 245) and 
without (right, n = 242), across different mutation types. The inset box 
corresponds to the first and third quartiles of the distribution, the horizontal 
line indicates the median and whiskers include data within 1.5× the IQR from 
the box.
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Extended Data Fig. 5 | Correlation between the league model and Bradley–
Terry model ordering. Direct comparison for each tumour type of the league 
and Bradley–Terry models for determining the order of recurrent somatic 
mutations and copy number events. Axes indicate the ordered events observed 
in the respective tumour types. Correlation is quantified by Spearman’s rank 
correlation coefficient. A total of n = 756 ordered events are shown.
Extended Data Fig. 6 | Examples of mutation spectrum changes across 
tumour evolution. a, Three examples of tumours with substantial changes 
between mutation spectra of early (top) and late (bottom) clonal time points.  
b, Three examples of tumours with substantial changes between mutation 
spectra of clonal (top) and subclonal (bottom) time points.
Article
Extended Data Fig. 7 | Overview of early-to-late clonal and clonal-to-
subclonal signature changes across tumour types. a, b, Pie charts 
representing signature changes per cancer type for early-to-late clonal 
signature changes (a) and clonal-to-subclonal signature changes (b). 
Signatures that decrease between early and late are coloured green; signatures 
that increase are purple. The size of each pie chart represents the frequency of 
each signature. Signatures are split into three categories: (1) clock-like, 
comprising the putative clock signatures 1 and 5; (2) frequent, which are 
signatures present in ten or more cancer types; and (3) cancer-type specific, 
which are in fewer than ten cancer types and are often limited to specific 
cohorts.
Extended Data Fig. 8 | See next page for caption.
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Extended Data Fig. 8 | Age-dependent mutation burden and relapse samples 
indicate near-normal CpG>TpG mutation rate in cancer, with moderate 
acceleration during carcinogenesis. a, Across all cancer samples, a 
predominantly linear accumulation of CpG>TpG mutations (scaled to copy 
number) is observed over time, as measured by the age at diagnosis. b, Cancer-
specific analysis of the CpG>TpG mutation burden as a function of age at 
diagnosis for n = 1,978 samples of 34 informative cancer types. The dotted line 
denotes the median mutations per year (that is, not offset), and shading 
denotes the 95% credible interval of a hierarchical Bayesian linear regression 
model across all data points. Slope and intercepts are drawn for each cancer 
type from a gamma distribution, respectively; inference was done by 
Hamiltonian Monte Carlo sampling. c, Maximum a posteriori estimates of  
rate and offset for 34 cancer types with 95% credible intervals as defined in b.  
d, Mutation rate inferred from cancer as in b and from selected normal tissue 
sequencing studies of n = 140 normal haematopoietic stem cells, n = 1 normal 
skin sample, n = 182 samples from normal endometrium, and n = 445 normal 
colonic crypts; error bars denote the 95% confidence interval. e, Median 
fraction of mutations attributed to linear age-dependent accumulation, based 
on estimates from b and the age at diagnosis for each sample. Error bars denote 
the 95% credible interval. f, g, CpG>TpG mutations per gigabase for ovarian 
cancer (f) and breast cancer (g) samples with matched primary and relapse 
samples. h, Increase in CpG>TpG mutation rate inferred from paired primary 
and relapse samples for six cancer types. Bars denote the range of the rate 
increase for different scenarios of copy number evolution, assuming ploidy 
changes have occurred prior (upper value) or posterior (lower value) to the 
branching between primary and relapse sample.
Extended Data Fig. 9 | Real-time estimates indicate long latencies for some 
samples caused by the absence of early mutations. a, Time of WGD for n = 571 
individual patients, split by tumour type with an estimated mutation rate 
increase of 5×, except for ovary–adenocarcinoma (7.5×) and CNS (2.5×). Error 
bars represent 80% confidence intervals, reflecting uncertainty stemming 
from the number of mutations per segment and onset of the rate increase. Box 
plots demarcate the quartiles and median of the distribution with whiskers 
indicating 5% and 95% quantiles. b, Scatter plots showing the time of diagnosis 
(x axis) and inferred time of WGD (y axis) with error bars as in a. c, Scatter plot of 
early (co-amplified) CpG>TpG mutations (y axis) as a function of the mutational 
time estimate of WGD (x axis). The black line denotes a nonlinear loess fit with 
95% confidence interval. Colours define the cancer type as in a. d, Total 
CpG>TpG mutations (y axis) as a function of the mutation time estimate of 
WGD (x axis). Colours and fit as in c. Early molecular timing is thus caused by a 
depletion of early CpG>TpG mutations, rather than an inflation of late 
CpG>TpG mutations. e, Estimated median WGD latency of n = 571 patients as in 
a for fixed (x axis) versus patient specific rate increases, depending on the 
observed CpG>TpG mutation burden, allowing for a higher (up to 10×) 
mutation rate increase in samples with more mutations (y axis). Error bars 
denote the IQR. f, Timing of subclonal diversification using CpG>TpG 
mutations in n = 1,953 individual patients. Box plots and error bars for data 
points as in a. g, Comparison of the median duration of subclonal 
diversification per cancer type assuming branching and linear phylogenies.
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